An evaluation of a pilot of daily testing of SARS-CoV-2 contacts in acute hospital and ambulance trusts in England.

COVID-19 Daily contact testing Healthcare workers Lateral flow SARS-CoV-2

Journal

Public health
ISSN: 1476-5616
Titre abrégé: Public Health
Pays: Netherlands
ID NLM: 0376507

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 08 03 2022
revised: 17 05 2022
accepted: 19 05 2022
pubmed: 10 7 2022
medline: 19 8 2022
entrez: 9 7 2022
Statut: ppublish

Résumé

Healthcare worker (HCW) SARS-CoV-2 contacts in England have been required to quarantine, creating staff shortages. We piloted daily contact testing (DCT) to assess its feasibility as an alternative. Observational service evaluation. We conducted an observational service evaluation of 7-day DCT using antigen lateral flow devices (LFDs) at four acute hospital trusts and one ambulance trust in England. Mixed methods were used, using aggregate and individual-level test monitoring data, semi-structured interviews, and a survey of eligible contacts. In total, 138 HCWs were identified as contacts of a confirmed SARS-CoV-2 case. Of these, 111 (80%) consented to daily LFD testing, of whom 82 (74%) completed the required programme without interruption and 12 (11%) completed with interruption. Fifty-eight participants (52%) and two non-participants (7.4%) completed the survey. In total, 28 interviews were conducted with participants, site and infection control leads, and union representatives. One participant tested positive on LFD and polymerase chain reaction (PCR) test. Three participants tested positive on PCR but not LFD. DCT was well-accepted by trusts and staff. Participants reported no relaxation of their infection prevention and control behaviours. No incidents of transmission were detected. An estimated 729 potential days of work absence were averted. DCT can be acceptably operated in a healthcare setting, averting quarantine-related work absences in HCW SARS-CoV-2 contacts.

Identifiants

pubmed: 35809350
pii: S0033-3506(22)00140-8
doi: 10.1016/j.puhe.2022.05.013
pmc: PMC9174334
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

46-51

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Références

Lancet. 2021 Apr 17;397(10283):1425-1427
pubmed: 33609444
Lancet Microbe. 2021 Sep;2(9):e461-e471
pubmed: 34226893
Lancet. 2021 Oct 2;398(10307):1217-1229
pubmed: 34534517
Lancet. 2021 May 8;397(10286):1725-1735
pubmed: 33901423
Lancet Public Health. 2021 Mar;6(3):e175-e183
pubmed: 33484644
Front Public Health. 2021 Aug 03;9:714041
pubmed: 34414160
BMC Public Health. 2021 Jun 5;21(1):1067
pubmed: 34090404
BMJ. 2021 Jul 8;374:n1741
pubmed: 34244210
J Med Microbiol. 2022 Aug;71(8):
pubmed: 35947525
PLoS Comput Biol. 2022 May 27;18(5):e1010158
pubmed: 35622860

Auteurs

S M A Bow (SMA)

NHS Test and Trace, Department of Health and Social Care, UK. Electronic address: steve.bow@nhs.net.

A Goddard (A)

NHS Test and Trace, Department of Health and Social Care, UK.

G Cope (G)

NHS Test and Trace, Department of Health and Social Care, UK.

N Sharp (N)

NHS Test and Trace, Department of Health and Social Care, UK.

C Woods (C)

Lancashire Teaching Hospitals NHS Foundation Trust, Lancashire, UK.

K Jeffery (K)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

D Harrington (D)

Barts Health NHS Trust, London, UK.

S Williams (S)

Royal Free London NHS Foundation Trust, London, UK.

A J Rodger (AJ)

Royal Free London NHS Foundation Trust, London, UK.

S Finer (S)

NHS Test and Trace, Department of Health and Social Care, UK.

T Fowler (T)

NHS Test and Trace, Department of Health and Social Care, UK; William Harvey Research Institute, Queen Mary University of London, London, UK.

S Hopkins (S)

NHS Test and Trace, Department of Health and Social Care, UK; Public Health England, UK.

S A Tunkel (SA)

NHS Test and Trace, Department of Health and Social Care, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH